These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30187607)

  • 21. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
    Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C;
    J Viral Hepat; 2018 Dec; 25(12):1526-1532. PubMed ID: 30141261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of telehealth to increase treatment access for prisoners with chronic hepatitis C.
    Halder A; Li VG; Sebastian M; Nazareth S; Tuma R; Cheng W; Doyle A
    Intern Med J; 2021 Aug; 51(8):1344-1347. PubMed ID: 34423535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthcare-associated hepatitis B and C transmission to patients in the EU/EEA and UK: a systematic review of reported outbreaks between 2006 and 2021.
    Singh J; Stoitsova S; Zakrzewska K; Henszel L; Rosińska M; Duffell E
    BMC Public Health; 2022 Dec; 22(1):2260. PubMed ID: 36463162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
    Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
    Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review.
    Kronfli N; Linthwaite B; Kouyoumdjian F; Klein MB; Lebouché B; Sebastiani G; Cox J
    Int J Drug Policy; 2018 Jul; 57():95-103. PubMed ID: 29715590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review.
    Hofstraat SHI; Falla AM; Duffell EF; Hahné SJM; Amato-Gauci AJ; Veldhuijzen IK; Tavoschi L
    Epidemiol Infect; 2017 Oct; 145(14):2873-2885. PubMed ID: 28891457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Telemedicine efficiently improves access to hepatitis C management to achieve HCV elimination in the penitentiary setting.
    Cuadrado A; Cobo C; Mateo M; Blasco AJ; Cabezas J; Llerena S; Fortea JI; Lázaro P; Crespo J
    Int J Drug Policy; 2021 Feb; 88():103031. PubMed ID: 33221615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancing assessment and treatment of hepatitis C in the custodial setting.
    Post JJ; Arain A; Lloyd AR
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S70-4. PubMed ID: 23884069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience.
    Winter RJ; Holmes JA; Papaluca TJ; Thompson AJ
    Viruses; 2022 Feb; 14(3):. PubMed ID: 35336905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
    J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
    Ioannou GN; Feld JJ
    Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners.
    Beckman AL; Bilinski A; Boyko R; Camp GM; Wall AT; Lim JK; Wang EA; Bruce RD; Gonsalves GS
    Health Aff (Millwood); 2016 Oct; 35(10):1893-1901. PubMed ID: 27702964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Seroprevalence of hepatitis C virus infection at the time of entry to prison in the prison population in the north-east of Spain].
    Martín Sánchez V; Ferrer Castro V; Pallas Álvarez JR; Alonso Herrero LE; Andrés Honorato M; Coterillo González MJ; García Marcos LS; González Márquez J; Hernández Alonso I; LLanos Gallegos M; Mallada García E; Martínez Martínez ML; Morillo Pérez M; Pérez Martínez I; Valles Martínez J
    Rev Esp Salud Publica; 1998; 72(1):43-51. PubMed ID: 9477715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus infection in EU/EEA and United Kingdom prisons: a descriptive analysis.
    Nakitanda AO; Montanari L; Tavoschi L; Mozalevskis A; Duffell E
    Epidemiol Infect; 2021 Jan; 149():e59. PubMed ID: 33487201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.
    Coward S; Leggett L; Kaplan GG; Clement F
    BMJ Open; 2016 Sep; 6(9):e011821. PubMed ID: 27601496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.
    Falla AM; Ahmad AA; Duffell E; Noori T; Veldhuijzen IK
    BMC Infect Dis; 2018 Jan; 18(1):42. PubMed ID: 29338702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eradicating hepatitis C from the New South Wales prison system.
    Blogg J; Wood J; McGrath C; Lobo C
    Med J Aust; 2018 Apr; 208(6):276. PubMed ID: 29614945
    [No Abstract]   [Full Text] [Related]  

  • 38. Development and optimisation of a reception testing protocol designed to eliminate HCV in the UK prison population.
    Mongale E; Allen S; Brew I; Ludlow-Rhodes A; Royal N; Waldron J; Alexander H; Christensen L; Dorrington K; Milner A; Missen L; Jones A; Troke PJF
    JHEP Rep; 2024 Jan; 6(1):100937. PubMed ID: 38169900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is global elimination of HCV realistic?
    Calvaruso V; Petta S; Craxì A
    Liver Int; 2018 Feb; 38 Suppl 1():40-46. PubMed ID: 29427499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.